Furthermore, a mechanistic study revealed that monocytes chemoattractant protein-1 (MCP-1) was responsible for this improvement, suggesting a promising therapeutic candidate in future renal tissue engineering strategy for diabetes. This evidence concerns the gene CCL2 and diabetes mellitus.